| ID | 1120 |
| Name of the vaccine | PedaTyph |
| Microbe | Bacteria |
| Disease name | Typhoid |
| Name of bacteria | Salmonella typhi |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | From 3 months |
| Description of the vaccine | Purified Vi capsular polysaccharide of Salmonella typhi (Strain Ty2) conjugated with Tetanus toxoid protein. |
| Name of the manufacturer | BIO-MED Private Limited |
| Name of the manufacturing country | India |
| Year of manufacture | 2008 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | Efficacy has been found to be 100% over a follow up period of 1 year. |
| Vaccine formulation | Turbid solution |
| Dosage | Single dose followed by booster after 2.5-3 years of primary vaccination. |
| Mechanism of action | T cell dependent response. |
| Route of administration | Intramuscular |
| Indications | Active immunization against Salmonella typhi in infants, children and adults. |
| Export | Marketed by: BIO-MED Private Limited, India |
| Approval | Licensed in India and not WHO prequalified |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Pain, induration, erythema, purities at the injection site. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | http://www.biomed.co.in/peda-typh/ |
| Other name | NA |
| Additional Links | https://www.jcdr.net/article_fulltext.asp?id=5903
|